Medicare and Medicaid
Our work in Medicare and Medicaid
-
Cost- Effectiveness of Total State Coverage for Hepatitis C Medications
A Medicaid-Medicare partnership could cover lifesaving hepatitis C medications — and still save $1 to $1.1 billion over 25 years.
Categorized in -
The Effects of Vertically Integrated Care on Health Care Use and Outcomes in Inpatient Rehabilitation Facilities
Receiving vertically integrated care in hospital-based inpatient rehabilitation facilities shortens institutional length of stay while maintaining or improving health outcomes.
Categorized in -
Association of Drug Rebates and Competition With Out-of-Pocket Coinsurance in Medicare Part D, 2014 to 2018
Research from Schaeffer Center experts Darius Lakdawalla and Meng Li in JAMA Network Open finds U.S. insurers could use drug manufacturer rebates to lower retail pharmacy prices and reduce patient out-of-pocket burden by 38% on average, or 70% in the most competitive drug classes.
Categorized in -
Advance Care Planning for Medicare Beneficiaries Increased Substantially, but Prevalence Remained Low
Researchers examined fee-for-service Medicare claims and found a substantial increase in outpatient advance care planning claims between 2016 and 2019, although prevalence remained below 7.5 percent for all patient subgroups analyzed.
Categorized in -
Medicare Advanced Imaging Payment: Dysfunctional Policy Making
Medicare’s experience of paying for outpatient imaging services, particularly expensive advanced imaging such as MRIs, CAT scans, and nuclear scans, has been tumultuous over the last 20 years.
Categorized in -
Will Medicare Run Out of Money?
Join the Bipartisan Policy Center, the American Enterprise Institute, and the USC-Brookings Schaeffer Initiative for Health Policy for a panel discussion with congressional staff and experts to examine policy options that can avert the worst outcomes and place the Medicare program on a better track.
Categorized in -
Schaeffer Solutions: Health Policy Recommendations for the Biden Administration and 117th U.S. Congress
The USC-Brookings Schaeffer Initiative for Health Policy has developed practical recommendations and analysis in a number of critical policy areas.
Categorized in -
Medicare Payment for Physician-Administered (Part B) Drugs: The Interim Final Rule and a Better Way Forward
A look at how policymakers can reform an interim-final rule to use Medicare’s demonstration authority under the Center for Medicare and Medicaid Innovation (CMMI) to make large reductions in the amounts it pays physicians for high-cost medicines they administer under Part B.
-
Monthly Cost Sharing Doubles Throughout the Year for Some Medicare Insulin Users
Schaeffer Center researchers examined how use of insulin changes as cost-sharing fluctuates over the course of the year for Medicare Part D beneficiaries.
-
Without Reform, Medicare Policies Will Hamstring New Gene Therapies
It took until the fall of 2020 – three years after FDA approval – for Medicare to consistently pay an adequate amount for CAR-T therapy.
Categorized in